Skip to main content
. Author manuscript; available in PMC: 2019 Oct 1.
Published in final edited form as: Neuropharmacology. 2018 Sep 7;141:260–271. doi: 10.1016/j.neuropharm.2018.09.005

Figure 6. MMP-2200 reduces both D2R agonist-induced LAO and locomotor AIMs.

Figure 6.

(A)The graph shows mean total LAO AIMs scores (± SEM). MMP-2200 (20 mg/kg, i.p.) significantly reduces quinpirole (0.2 mg/kg, i.p.)-induced LAO AIMs by ~40%. (B) The graph depicts mean total locomotor AIMs scores (± SEM) following quinpirole injection; MMP-2200 (20 mg/kg, i.p.) co-administration efficiently blocks locomotor AIMs. (C) The graph shows the time-course of the action of MMP-2200 on D2R agonist-induced LAO-AIMs. (D) The graph depicts the time-course of action of MMP-2200 on D2R agonist-induced locomotor AIMs. In all graphs data were acquired over a 180 min period following administration of drugs, using a within-subjects crossover design (*p < 0.05; n = 7).